UK Mid-Caps Beat: Derwent, Serco, Hikma Post Strong H1 and Lift Guidance
Three London-listed mid-caps—Derwent London, Serco Group, and Hikma Pharmaceuticals—reported H1 results that collectively beat expectations and prompted guidance upgrades or reiteration. With rental growth at a decade high, defence spending flowing to outsourcers, and pharma injectables recovering, the results signal robust sectoral momentum despite geopolitical and macro risks.
Finance briefing
Key takeaways
- Three London-listed mid-caps—Derwent London, Serco Group, and Hikma Pharmaceuticals—reported H1 results that collectively beat expectations and prompted guidance upgrades or reiteration.
- With rental growth at a decade high, defence spending flowing to outsourcers, and pharma injectables recovering, the results signal robust sectoral momentum despite geopolitical and macro risks.
In this briefing
Mentioned
Key Intelligence
Key Facts
- 1Derwent London’s estimated rental value growth hit 2.6% in H1 2026—its highest first-half increase in a decade—and it upgraded full-year earnings outlook.
- 2AI-related office take-up in London reached 700,000 sq ft in H1 2026, nearly double the full-year 2025 total, with a further 600,000 sq ft of active demand.
- 3Serco Group’s underlying operating profit rose to £157 million, with constant-currency revenue growth of 4% driven by defence activities and productivity gains.
- 4Hikma Pharmaceuticals reported EBIT and EBITDA each up nearly 8%, with EPS up 5%, and reiterated full-year guidance despite planned higher R&D and promotional spend in H2.
- 5Derwent’s EPRA vacancy rate stood at just 4.4% (3.5% ex-88-94 TCR), and West End Grade A vacancy was a razor-thin 1.2%.
- 6Hikma’s branded MENA unit benefited from government stockpiling early in 2026 due to regional conflict, though this effect normalised towards the end of H1.
| Metric | |||
|---|---|---|---|
| Revenue/Income Growth | N/A (rental growth 2.6%) | +4% CC | Mid-single-digit |
| Key Profit Metric | Upgraded earnings outlook | Underlying OP £157M | EBIT +8% |
| Guidance | Upgraded | Maintained | Reiterated |
| Key Driver | AI office demand | Defence spending | Injectables stabilisation |
Analysis
For investors in UK equities, the synchronised earnings beats from these three companies offer a window into the divergent drivers of post-Brexit, post-pandemic British growth. Derwent’s AI property play, Serco’s defence tailwind, and Hikma’s drug depth each represent a distinct alpha stream, but together they underscore that active stock selection in the mid-cap space is being rewarded—provided one navigates the regional and interest-rate cross-currents.
Three London-listed companies—Derwent London, Serco Group, and Hikma Pharmaceuticals—reported first-half 2026 earnings on August 9, each painting a picture of resilient UK corporate performance amid an uncertain macroeconomic backdrop. The thematic threads running through the reports include: stronger-than-expected operating metrics prompting upgraded or reiterated guidance; geopolitical tailwinds and headwinds from defense spending and regional instability; and the emerging role of artificial intelligence in reshaping demand across sectors from offices to pharmaceuticals.
Hikma Pharmaceuticals reiterated full-year guidance after reporting near-8% EBIT growth and 5% EPS growth.
Derwent London, the central London office REIT, delivered a standout performance as the West End's chronic supply shortage collided with surging demand—particularly from AI companies. Executive Director Emily Prideaux noted that AI-related office take-up hit 700,000 square feet in the first half, nearly double the entire 2025 total, with a further 600,000 square feet of unsatisfied demand. This contributed to Derwent's highest first-half estimated rental value growth in a decade at 2.6%, accelerating from prior periods, and management upgraded its full-year earnings outlook. The EPRA vacancy rate fell to just 4.4%, and new leases were signed 5.1% above estimated values. Meanwhile, Grade A West End vacancy was a razor-thin 1.2%, underscoring the supply crunch that proptech innovators and flexible workspace operators must navigate. Yet tenant incentives stubbornly remain around 24 months on a 10-year lease, reflecting construction-cost inflation and cautious occupier sentiment despite the headline demand. This tension between bidding pressure and incentive structures is a key dynamic to monitor.
Serco Group, the government services outsourcer, reported constant-currency revenue growth of 4% and underlying operating profit of £157 million. Defense activity was a primary growth driver—hardly surprising given elevated government defense budgets across the UK, Europe, and North America. CEO Anthony Kirby credited productivity initiatives and cost control for margin expansion. The company maintained full-year guidance and expanded its share buyback program, signaling confidence in sustained public-sector outsourcing demand. Serco’s results underscore the booming defense-technical services market, which increasingly integrates digital and cybersecurity capabilities—creating crosswind with the proptech and AI ecosystems as modern defense infrastructure demands smart bases and secure data centers.
What to Watch
Hikma Pharmaceuticals reiterated full-year guidance after reporting near-8% EBIT growth and 5% EPS growth. CEO Said Darwazah stabilised the critical injectables business, a turnaround from prior headwinds, and expressed confidence that injectables will contribute more meaningfully from next year onward. The branded MENA division benefited from early-year government stockpiling due to regional conflict, but that effect normalized later in the half. Acting CFO Areb Kurdi highlighted that 55% of annual branded sales typically fall in H1 due to tender seasonality, and that postponed promotional expenses will hit H2. R&D spending is set to increase in H2, along with senior hires, as Hikma positions for a higher-margin injectables future. Geopolitical volatility and currency risk in the MENA region remain a concern, but Hikma’s three engines—injectables, branded MENA, and Rx—appear to be firing in unison.
Collectively, these results suggest London’s listed mid-caps are navigating global disruptions with agility. Derwent’s results reflect how the AI talent war is reshaping real estate demand, Serco shows that defense spending is flowing through to private contractors, and Hikma illustrates that pharma can thrive even as supply chains remain fragile. For investors, the trio provides a microcosm of the UK market’s evolving drivers: technology absorption, government spending, and healthcare resilience. The second half will test whether the upgraded guidance from Derwent, sustained momentum at Serco, and Hikma’s injectables recovery can withstand consumer price pressures, interest rate uncertainty, and geopolitical flare-ups. All three management teams struck cautiously optimistic tones, but the clear message is that the post-pandemic reorientation of capital toward AI, defense, and essential medicines is creating lasting structural advantages.
Cite This Page
"UK Mid-Caps Beat: Derwent, Serco, Hikma Post Strong H1 and Lift Guidance." Finance Intelligence Brief, August 10, 2026. https://getfinancebrief.com/story/uk-mid-caps-earnings-derwent-serco-hikma-h1-2026
How we covered this story
Every story in our finance coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the finance space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
Sources are only linked to a story once they clear our classification pipeline at a minimum 35 percent relevance threshold. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong in this story — a wrong fact, a broken source link, a misattributed entity? Report a data issue.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled finance-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |